Platelet-rich plasma (PRP) showed slightly better score improvements than dextrose prolotherapy for knee osteoarthritis in randomized trial testing at six months, but the difference between the two treatments was modest. In the guides we publish here, readers often ask whether paying for concentrated blood platelets delivers a measurable advantage over an injection series based on medical-grade sugar water. No PRP product holds Food and Drug Administration (FDA) approval for joint use, and PRP is rarely covered by insurance.
Choosing between PRP and dextrose prolotherapy comes down to comparing published trial outcomes, evaluating documented post-injection soreness rates, and understanding what each clinic includes in an injection series.
PRP vs prolotherapy at a Glance
| Criteria | PRP (platelet-rich plasma) | Prolotherapy (dextrose) |
|---|---|---|
| What is injected | Concentrated platelets separated from your own blood | An irritant solution, most commonly hypertonic dextrose |
| FDA regulatory status | Not FDA-approved for joint use (used off-label) | No FDA approval for joint osteoarthritis on our record |
| Trial regimen studied | 3 injections spaced 3 weeks apart (leukocyte-poor, 3 mL) | 3 injections spaced 3 weeks apart (25% dextrose, 6 mL) |
| Walking pain at 6 months | Better by 0.42 cm on the visual analog scale | Improved from baseline, but trailed PRP slightly |
| Function score at 6 months | Better by 7.64 points on the Lysholm scale | Improved from baseline, but trailed PRP slightly |
| Flexion range of motion | Higher by 3.68 degrees at 6 months | Improved from baseline, but trailed PRP slightly |
| Post-injection soreness | 18.8% transient soreness in trial testing | 15.3% transient soreness in trial testing |
| Typical US pricing | $500 to $2,500 per course (Medical Frontier estimate) | Unpublished US range; clinics set pricing individually |
What Each Injection Delivers
The central physical difference between PRP and prolotherapy lies in the source material placed inside the joint.
Platelet-rich plasma (PRP) begins with a standard draw of your own blood. A clinical provider concentrates that blood using a centrifuge. The resulting preparation isolates and concentrates platelets before injection. These concentrated platelets are re-injected into the target joint space or surrounding tendon structures.
Prolotherapy uses a manufactured irritant solution rather than biologic material extracted from your body. The most common irritant agent is hypertonic dextrose, a concentrated medical sugar solution. A clinician injects this dextrose solution into the intra-articular joint space or around supporting ligaments and tendons. Prolotherapy uses an irritant dextrose solution, whereas PRP supplies concentrated autologous blood components directly into the joint or tendon.
What the Head-to-Head Knee Trial Found
Direct head-to-head evidence comparing these two modalities for knee osteoarthritis comes from a randomized controlled trial published in the Journal of Surgery and Medicine (Vol. 10, No. 8, published August 3, 2026).
This trial enrolled 105 patients aged 40 to 70 with Kellgren-Lawrence grade II to grade III knee osteoarthritis. Researchers randomized participants into two parallel arms: 53 patients received PRP injections and 52 patients received dextrose prolotherapy injections. Both groups followed an identical administration schedule consisting of three injections spaced three weeks apart. In addition to the injection series, every participant completed a standardized quadriceps-strengthening exercise program throughout the study.
The specific preparation protocol used 3 mL of leukocyte-poor PRP with an estimated 4 to 5 times baseline platelet concentration for the PRP cohort. The prolotherapy cohort received 6 mL of 25% hypertonic dextrose administered intra-articularly. Investigators tracked patient progress at baseline, at 3 months, and at 6 months following treatment.
Patients in both arms experienced statistically significant improvements from baseline from baseline to 6 months. However, PRP established a statistically significant advantage over dextrose prolotherapy across three primary physical outcomes:
- Walking pain on the visual analog scale (VAS) showed an adjusted mean difference of 0.42 cm favoring PRP (95% confidence interval [CI] 0.08 to 0.76).
- Joint function evaluated on the Lysholm scale favored PRP by an adjusted mean difference of 7.64 points (95% CI 0.32 to 14.96).
- Knee flexion range of motion favored PRP by an adjusted mean difference of 3.68 degrees.
Critically, the study authors emphasized that while these between-group differences favored PRP with statistical significance, the absolute clinical margins remained modest. The trial did not follow patients beyond 6 months, leaving longer-term relative durability unanswered in this specific cohort.
Systematic Review Evidence and Other Injectables
Broader medical literature confirms that head-to-head comparisons between dextrose prolotherapy and autologous blood injections remain limited in total volume.
A 2019 systematic review published in Advances in Rheumatology pooled data from 10 randomized controlled trials evaluating hypertonic dextrose prolotherapy for knee osteoarthritis against other injection therapies. The authors of that review concluded that dextrose prolotherapy was less effective than PRP for reducing pain and improving physical function scores. At the same time, the review noted that direct comparisons between prolotherapy and PRP rested on relatively few individual clinical trials, and it documented zero serious adverse reactions linked to hypertonic dextrose injections across the pooled cohorts.
To place PRP outcomes in wider clinical context, a meta-analysis of 14 randomized controlled trials covering 1,512 patients published in PubMed Central examined PRP against hyaluronic acid (HA). That analysis found no measurable difference in clinical efficacy between PRP and hyaluronic acid at 1 month post-injection, but identified a performance gap favoring PRP by 12 months.
FDA Regulatory Status and Safety Profiles
FDA regulatory status differs between these approaches.
No PRP preparation is approved by the agency for joint disease, and clinics administering these treatments inject the substance off-label. The Food and Drug Administration publishes a dedicated consumer alert regarding unapproved regenerative medicine therapies. Similarly, our records show no FDA approval of dextrose prolotherapy for joint osteoarthritis. Patients considering dextrose injections should confirm the current regulatory standing of the specific protocol directly with their treating clinic and the FDA.
Regarding procedural safety, neither approach produced serious adverse events in the 2026 head-to-head trial. Mild, transient post-injection soreness occurred in both groups: 18.8% of patients receiving PRP and 15.3% of patients receiving dextrose prolotherapy reported temporary discomfort after their injections. The difference in soreness rates between the two treatments was not statistically significant. The 2019 systematic review similarly reported no serious adverse reactions connected to dextrose prolotherapy across multiple trials.
Out-of-Pocket Pricing and Quote Checklists
Health insurance policies rarely provide coverage for PRP joint injections. Our internal pricing estimate benchmarks a typical PRP course between $500 and $2,500. Individual clinics set their own prices. You can explore how clinical variables influence these self-pay figures using our PRP injection cost guide and our detailed breakdown of insurance coverage policies for PRP.
For dextrose prolotherapy, US pricing ranges remain unpublished. Costs vary substantially from one private practice to another.
Before scheduling either injection series, obtain a written, itemized financial estimate from the provider. Ensure your quote clarifies four essential details:
- The exact number of injection appointments included in the quoted total price.
- Whether the procedure involves image guidance, such as ultrasound visualization, and whether guidance carries a separate billing fee.
- The exact volume and formulation injected, such as the dextrose concentration percentage or leukocyte composition.
- Any additional facility fees, physician evaluation charges, or post-injection follow-up visit expenses.
Who This Is Not For
Patients who cannot pay out of pocket should avoid private clinic proposals for either therapy. PRP is rarely covered by insurance, which requires patients to pay out of pocket.
What Would Change This Answer
Our current assessment that PRP holds a modest statistical advantage over dextrose prolotherapy rests primarily on the August 2026 randomized controlled trial and the 2019 systematic review. Specific future clinical trial data could alter this comparative balance.
A larger, multi-center randomized controlled trial tracking patients past 12 months that demonstrates no functional separation between dextrose prolotherapy and PRP would neutralize PRP’s clinical edge. Conversely, if a multi-year trial reveals that prolotherapy produces accelerated joint space narrowing or repeated soft-tissue irritation, safety calculations would move decisively in favor of autologous blood preparations.
How to Decide Between PRP and Prolotherapy
When weighing a recommendation between these two injection paths, follow this practical decision sequence:
- Review your baseline joint imaging. Patients in the 2026 randomized trial had Kellgren-Lawrence grade II to III osteoarthritis.
- Request an itemized written quote. Compare the clinic’s total multi-injection cost against our $500 to $2,500 benchmark for PRP, and ask how many injections a series includes.
- Evaluate the clinical margins. Determine whether PRP’s modest trial advantages (0.42 cm on walking pain and 7.64 points on the Lysholm scale at 6 months) justify the price premium your clinic quotes.
- Confirm the provider’s protocol. Verify whether the clinic administers three sessions spaced several weeks apart, matching the published trial methodology, and confirm whether they pair the series with structured quadriceps exercise.
The Bottom Line on PRP vs Prolotherapy
Randomized trial evidence demonstrates that both PRP and dextrose prolotherapy groups improved significantly from baseline over a 6-month period when combined with quadriceps exercises. PRP holds a statistically verified performance advantage across pain, function scores, and range of motion at 6 months, but clinical trial investigators explicitly described this separation as modest. Because PRP lacks FDA approval for joint use and is rarely covered by insurance, the financial gap between your clinic’s quotes often dictates the decision.
Obtain written, itemized quotes for both injection series from your orthopedic provider and evaluate the exact cost premium charged for PRP vs prolotherapy before scheduling your first appointment.
Frequently asked questions
What is the difference between PRP and prolotherapy?
PRP uses concentrated platelets separated from your own blood, while prolotherapy uses an injected irritant solution, most commonly hypertonic dextrose sugar water. PRP introduces autologous blood components, whereas prolotherapy uses an irritant dextrose solution.
Is prolotherapy better than PRP for knee pain?
Published clinical trial evidence does not show prolotherapy outperforming PRP. In a 2026 randomized controlled trial of 105 knee osteoarthritis patients, PRP achieved statistically superior improvements at 6 months for walking pain, Lysholm function scores, and knee flexion, though study authors noted the differences between groups were modest.
Which treatment costs more, PRP or prolotherapy?
A full course of PRP generally runs between $500 and $2,500 out of pocket. Prolotherapy pricing ranges in the United States remain unpublished and vary by clinic, requiring direct itemized quotes from providers.
Are PRP and prolotherapy injections FDA-approved for knee osteoarthritis?
No PRP product carries FDA approval for joint use. Clinics administer PRP off-label, and the FDA has issued a consumer alert regarding unapproved regenerative medicine therapies. No FDA approval for dextrose prolotherapy in joint osteoarthritis is documented on our record, so patients should verify regulatory status directly with their clinician and the FDA.
How many injections are required for PRP vs prolotherapy?
In the August 2026 head-to-head clinical trial, both the PRP cohort and the dextrose prolotherapy cohort received three injections spaced three weeks apart. Both groups also participated in a concurrent standardized quadriceps-strengthening program throughout the study.
Does health insurance cover prolotherapy or PRP injections?
Health insurance rarely covers PRP joint injections. Pricing and insurance coverage for dextrose prolotherapy are unpublished, so patients should request itemized quotes directly from their clinic.
Prolotherapy vs PRP: which should I try first?
Your decision should balance the modest performance advantage seen with PRP against the out-of-pocket cost quoted by your doctor. If a clinic charges a steep premium for PRP, the modest 0.42 cm walking pain separation seen in clinical testing may make dextrose prolotherapy worth exploring, provided your expectations account for trial outcomes.
Medical disclaimer. Medical Frontier is an independent educational resource. This page is for general information only and is not medical advice, diagnosis, or treatment, and does not create a doctor–patient relationship. Most regenerative therapies discussed here are not FDA-approved for the uses described and may be offered under limited exemptions or in clinical trials only. Always consult a licensed physician before making any treatment decision.